Effetto del lactobacillus paracasei I1688 e del lactobacillus salivarius I1794 (psmix®) sui lipidi ematici nell'ipercolesterolemia lieve

Translated title of the contribution: Effect of mixture 12: 1 lactobacillus paracasei I1688 and of lactobacillus salivarius I1794 (psmix®) on lipids in mild hypercholesterolemia

Roberto Fogari, Amedeo Mugellini, Tara Santoro, Ilaria Ferrari, Giuseppa Derosa

Research output: Contribution to journalArticle


The purpose of this study was to test the effect on hypercholesterolemia after the assumption of PSmix (Fiorilac® PS) in patient with mild hypercholesterolemia. The study population was aged between 35 and 65 years, affected by mild hypercholesterolemia (200-250 mg/dL) and never treated. Exclusion criteria were familial hypercholesterolemia, diabetes, ischemic heart disease, heart failure, previous stroke, high consumption of alcohol and/or concomitant treatment with diuretics and/or thyroid hormones. Thirty-eight patients were recruited into the study. After two weeks pre-treatment, patients fulfilling the inclusion criteria were instructed to assume daily PSmix for 12 weeks. The dietary habits of the patients were monitored using a questionnaire, but not modified by physicians; they also reported the use of drugs. After two weeks pre-treatment and after twelve weeks active treatment were evaluated plasma levels of total cholesterol (TC), HDL cholesterol (HDL-C) and triglycerides (Tg). LDL cholesterol (LDL-C) was calculated using the Friedewald formula. This study suggests that oral administration of PSmix is effective in improving lipid parameters in patients with mild hypercholesterolemia. It induces a modest but significant reduction in TC (8,6%, -18.4 mg/dl;

Original languageItalian
Pages (from-to)107-111
Number of pages5
JournalTrends in Medicine
Issue number2
Publication statusPublished - Apr 2010


ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology (medical)

Cite this